Mati Therapeutics Selected to Present at Ocular Innovation Summit

Pursuing Sustained Ocular Drug Delivery Programs in Inflammation, Pain, and Glaucoma

AUSTIN, Texas, October 03, 2016 (BUSINESS WIRE) -- Mati Therapeutics Inc. (“Mati”) announced that it has been selected to present at the annual Ocular Innovation Summit on October 13, 2016 in Chicago. Held in conjunction with the American Academy of Ophthalmology annual meeting, this invitation-only event highlights advanced and promising products, therapies, and companies in eye care.

Mati will present the development status of three new programs based on its ocular non-invasive sustained drug delivery platform, Evolute®. The first two programs are for treating patients with ocular inflammation and pain and will use a NSAID, nepafenac, and a steroid, difluprednate. The third program is a prostaglandin analogue that is designed for use in the treatment of glaucoma.

About Mati Therapeutics Inc.

Mati is developing Evolute®, a sustained ocular drug delivery platform that Mati believes has the potential to treat a range of ocular indications. The platform utilizes a device called a punctal plug, which is inserted into a patient’s tear duct (or punctum). The device has already been approved to treat dry eye syndrome, but Mati is the first to conduct clinical trials in the U.S. using punctal plugs as an anchoring device for a drug delivery platform. A drug-eluting core is inserted into Mati’s proprietary punctal plug, which allows medication to be continuously released into the tear film of the eye over a period of time. Mati believes Evolute® has the potential to become a more reliable alternative to several eye drop therapies, which can be ineffective because many patients are unwilling or unable to adhere to self-administered eye-drop regimens.

Mati has completed multiple Phase II clinical trials using the Evolute® platform, including multiple trials in glaucoma, ocular hypertension and allergy patients. Mati’s proprietary punctal plug design has demonstrated excellent lower punctum retention rates of up to 92% and 96% over a 12-week follow-up period in multiple multi-center U.S. clinical trials.

To learn more about Mati Therapeutics, visit

Contacts: Mati Therapeutics Inc.
Bob Butchofsky, CEO, 512-329-6360

View original press release